JAK2 and thrombocytosis disease: Essential thrombocythemia (ET), a myeloproliferative neoplasm frequently driven by JAK2 V617F mutations, results in thrombocytosis and hypercoagulability, elevating the risk of bleeding and thrombotic events including ischemic stroke.